title: Long-term inhalation of high-dose nitric oxide increases intraalveolar activation of coagulation system in mice.
abstract: Inhalation of nitric oxide (NO) is useful for the treatment of patients with pulmonary hypertension. However, the potential toxicity of inhaled NO is still unclear. Coagulation activation plays an important role in lung injury. We assessed the effect of low- and high-dose inhaled NO on the coagulation system in the intraalveolar space of mice. The animals were assigned to five groups (n = 6): [RA] group, mice exposed to fresh air alone; [RA+2 ppm NO] group, fresh air and 2 ppm NO; [RA+40 ppm NO] group, fresh air and 40 ppm NO; [RA+2 ppm NO+O(2)] group, fresh air, 2 ppm NO and O(2); and [RA+40 ppm NO+O(2)] group, fresh air, 40 ppm NO and O(2). Each group was treated for 3 wk. Lung specimens of [RA+40 ppm NO] and [RA+40 ppm NO+O(2)] groups showed significant nitrotyrosine immunoreactivity. BALF concentrations of total protein, thrombin and soluble tissue factor were significantly increased in mice of [RA+40 ppm NO] and [RA+40 ppm NO+O(2)] groups compared with [RA] group. However, BALF concentrations of total protein, thrombin, and soluble tissue factor were not significantly increased in mice of [RA+2 ppm NO] and [RA+2 ppm NO+O(2)] groups compared with [RA] group. Lung tissue factor mRNA expression was higher in the high-dose NO group than in the low-dose NO group. NO donor increased significantly tissue factor activity on alveolar epithelial cells. This study has shown for the first time that long-term inhalation of high, but not low, concentration of NO may activate the clotting system by increasing the lung expression of tissue factor.
authors.affiliation: Third Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: E C
authors.initials: EC
authors.lastname: Gabazza
authors.forename: S
authors.initials: S
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Yasui
authors.forename: H
authors.initials: H
authors.lastname: Yuda
authors.forename: O
authors.initials: O
authors.lastname: Hataji
authors.forename: K
authors.initials: K
authors.lastname: Maruyama
authors.forename: T
authors.initials: T
authors.lastname: Yamauchi
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
authors.forename: O
authors.initials: O
authors.lastname: Taguchi
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D001777:Blood Coagulation; D001980:Bronchi / Q000737:chemistry; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002460:Cell Line; D005260:Female; D007150:Immunohistochemistry; D008168:Lung / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009566:Nitrates / Q000032:analysis; D009569:Nitric Oxide / Q000008:administration & dosage / Q000633:toxicity*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D009573:Nitrites / Q000032:analysis; D009574:Nitro Compounds / Q000494:pharmacology; D011506:Proteins / Q000032:analysis; D011650:Pulmonary Alveoli / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013917:Thrombin / Q000378:metabolism*; D013925:Thromboplastin / Q000378:metabolism*; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000032:analysis
chemical_list: D009566:Nitrates; D020030:Nitric Oxide Donors; D009573:Nitrites; D009574:Nitro Compounds; D011506:Proteins; D009569:Nitric Oxide; C002744:3-nitrotyrosine; D014443:Tyrosine; D013925:Thromboplastin; C061872:FK 409; D013917:Thrombin